HBV

Bentysrepinine is an orally active inhibitor of the hepatitis B virus (HBV) that exhibits potent antiviral activity. It demonstrates favorable pharmacokinetic properties, with notable bioavailability across different species, including rats, dogs, and monkeys, and shows no accumulation in monkeys after 90 days of administration. This compound is being investigated for its potential applications in antiviral therapies and hepatitis research.

Daplusiran is a small interfering RNA (siRNA) designed to target and promote the degradation of hepatitis B virus (HBV) mRNAs. By inhibiting the replication of HBV, it serves as a vital tool in the development of therapeutic strategies for HBV-related diseases. Research applications include studies focused on liver disease and antiviral interventions.

HBV-IN-6 is a potent inhibitor of Hepatitis B Virus (HBV) with an EC50 value of 44 nM. This compound effectively interferes with viral replication, making it a valuable tool for research focused on HBV-related mechanisms and therapeutic strategies. Its efficacy underscores its potential application in developing effective treatments for HBV infections.

Antiviral Agent 38 is a potent inhibitor of the hepatitis B virus (HBV). This compound demonstrates significant antiviral activity, making it a valuable tool for research on HBV infections and their associated pathologies. Its efficacy positions it as an important reagent for studying HBV biology and potential therapeutic interventions.

HBV-IN-38 is an HBV DNA inhibitor, exhibiting an effective concentration (EC50) of ≤100 nM. This compound is primarily utilized in research to investigate the mechanisms of hepatitis B virus (HBV) infections and to evaluate potential therapeutic interventions against HBV replication.

Rolicyprine is a potent inhibitor of Hepatitis B Virus (HBV) that also exhibits neuroprotective activity. It has been shown to alleviate depressive symptoms and promote neuroregeneration, making it relevant for neuropsychiatric research. Additionally, Rolicyprine demonstrates potential in alleviating anxiety, indicating its applicability in studies related to mood disorders and HBV infections.

Erythrocentaurin is a natural compound that acts as an inhibitor of the hepatitis B virus (HBV). It exhibits potent antiviral activity, making it a promising candidate for research focused on HBV treatment and management. This compound can be utilized in studies aimed at understanding the mechanisms of HBV replication and the development of novel therapeutic strategies.

L-Fd4A is an adenine derivative that inhibits both human immunodeficiency virus (HIV) and hepatitis B virus (HBV) with effective concentrations (EC50) of 1.5 μM and 1.7 μM, respectively. This compound demonstrates promising antiviral activity while exhibiting low cytotoxicity, making it suitable for research applications in studying HIV and HBV inhibition mechanisms.

Di-Val-L-dC is a prodrug of L-deoxycytidine that targets hepatitis B virus (HBV) with specificity and selectivity. It exhibits potent antiviral activity against HBV, making it a valuable tool for research in viral infections and antiviral drug development. This compound provides insights into mechanisms of HBV replication and potential therapeutic interventions.

HBV-IN-37 is a selective inhibitor of Hepatitis B virus (HBV) with an EC50 value of 10 μM. This compound demonstrates significant antiviral activity, making it a valuable tool for researching therapeutic strategies against HBV infection. HBV-IN-37 is useful in elucidating the mechanisms of HBV replication and can serve as a lead compound in the development of antiviral agents targeting HBV.

Yhhu6669 is a potent inhibitor of Hepatitis B Virus (HBV), targeting HBV DNA replication. It functions by inducing the formation of DNA-free capsids, effectively reducing HBV levels. In preclinical studies using AAV/HBV-infected mouse models, Yhhu6669 demonstrated significant decreases in both HBV DNA and HBcAg. Additionally, it exhibits favorable pharmacokinetic properties, making it a valuable tool for research in HBV therapeutic development.

Tomligisiran is a small interfering RNA (siRNA) designed to target hepatitis B virus (HBV) mRNAs, promoting their degradation and effectively inhibiting HBV replication. This reagent plays a significant role in research focused on antiviral strategies and therapeutic approaches for HBV infections. Its utility in silencing HBV-specific RNA makes it a valuable tool for studying the molecular mechanisms of viral replication and pathogenesis.

HBV-IN-7 is a potent inhibitor of Hepatitis B Virus (HBV) with an EC50 of 7 nM. This compound effectively interferes with viral replication, making it a valuable tool for researching HBV pathogenesis and therapeutic interventions. Its strong antiviral activity supports applications in the development of treatments for chronic hepatitis B infections.

HBV-IN-8 is a potent inhibitor of hepatitis B virus (HBV) with an effective concentration (EC50) of 287.9 nM. This compound offers significant antiviral activity, making it a valuable tool for research applications focused on HBV infection and treatment mechanisms. HBV-IN-8 is suitable for investigations into the efficacy of antiviral agents in the pursuit of therapeutic strategies against HBV-related diseases.

CAB7-3 is an orally active capsid assembly modulator targeting Hepatitis B Virus (HBV), exhibiting potent antiviral activity. It demonstrates significant efficacy with EC50 values of 70 nM in HepDES19 cells, 1 nM in HepAD38 cells, and 2 nM in HBV-infected HLCZ01 cells. CAB7-3 effectively reduces hepatic HBV core protein levels and suppresses viral replication in vivo. This compound is valuable for research aimed at understanding and treating HBV infections.

GS-8873 is an orally active inhibitor targeting hepatitis B virus (HBV) surface antigen (HBsAg) production, exhibiting an EC50 of 4 nM. This compound demonstrates favorable pharmacokinetic properties in rat models and shows metabolic stability in human hepatocytes. While GS-8873 effectively suppresses HBV, it has been associated with neurofunctional deficits in both rats and cynomolgus monkeys, making it a subject of interest for further research into its biological effects and therapeutic potential.

(Rac)-AB-423 is a novel inhibitor targeting hepatitis B virus (HBV) with demonstrated antiviral activity. This compound has shown no induction of CYP1A2, CYP3A4, or CYP2B6 enzymes at elevated concentrations, indicating a favorable safety profile. Additionally, (Rac)-AB-423 exhibits advantageous pharmacokinetic characteristics, including high oral bioavailability and systemic exposure. In preclinical studies using a hydrodynamic injection HBV mouse model, (Rac)-AB-423 achieved a viral load reduction exceeding 2 log, highlighting its potential for therapeutic applications in HBV management.

Schisanwilsonin C is an anti-HBV agent that demonstrates significant activity against hepatitis B virus. This compound has been studied for its potential in antiviral research, offering insights into therapeutic strategies for managing HBV infections. Its efficacy in targeting viral replication makes it a valuable tool for further investigations in hepatitis B research.

(1R,3S,4R)-ent-Entecavir is an inhibitor of hepatitis B virus (HBV) replication, primarily targeting viral DNA polymerase. This compound is valuable for research applications focused on HBV control and offers potential for the development of PROTACs aimed at degrading viral DNA polymerase. Its structural analog attributes enhance its utility in studying antiviral mechanisms and therapeutic strategies against HBV infection.

HBV-IN-20 is a potent oral active inhibitor of Hepatitis B Virus (HBV), functioning primarily as a type II core protein assembly modulator (CpAM). With an EC50 of 0.46 µM, HBV-IN-20 disrupts the assembly of HBV core particles, thereby impeding viral replication. This compound is particularly valuable for research applications focused on antiviral therapy and understanding HBV biology.

AB-161 is an orally active HBV RNA destabilizer and a selective inhibitor of poly(A) polymerase domain-containing proteins 5 and 7 (PAPD5/7), primarily targeting hepatic tissues. This compound is effective in treating Hepatitis B Virus (HBV) infections by significantly reducing the levels of Hepatitis B surface antigen (HBsAg), with an EC50 value of 2.2 nM for HBsAg. AB-161 is a valuable tool for research applications focused on understanding and addressing HBV infection.

LP10 is a non-azole inhibitor targeting CYP51, showing potent activity against Hepatitis B Virus (HBV). This compound disrupts viral replication by inhibiting 14α-demethylation, which is critical for cholesterol biosynthesis in the virus. LP10 is useful for studying HBV infection mechanisms and evaluating antiviral strategies.

DVR-01 is a hepatitis B virus (HBV) inhibitor that exhibits antiviral activity in AML12HBV10 and HepDES19 cell lines, with EC50 values of 1.7 and 1.6 μM, respectively. This compound also demonstrates efficacy against drug-resistant HBV mutants, exhibiting EC50 values ranging from 2.403 to 3.273 μM. DVR-01 is suitable for research applications focused on HBV infection and associated diseases, contributing to the understanding of viral mechanisms and potential therapeutic interventions.

Lagociclovir valactate is a prodrug of Lagociclovir, designed for oral administration as an anti-hepatitis B virus (HBV) agent. It exhibits potent antiviral activity against HBV, making it valuable for research related to viral infections and hepatitis B treatment strategies. This compound aids in the exploration of effective therapeutic options in the management of HBV-related diseases.

KKJ00626 is a potent inhibitor of Hepatitis B virus (HBV) with an IC50 of 0.12 to 0.23 μM. This compound targets the interaction between HBV core protein and the surface protein PreS region, effectively preventing the maturation and secretion of HBV particles. Its significant antiviral activity makes KKJ00626 a valuable tool for research in HBV therapeutics and virology studies.

Dihydrodehydrodiconiferyl alcohol 9-O-β-D-xylopyranoside is a compound targeting hepatitis B virus (HBV) through the inhibition of HBV surface antigen (HBsAg) and HBV e antigen (HBeAg) secretion. This agent has demonstrated effective antiviral activity in the Hep G2.2.15 cell line, with IC50 values of 1.67 mM for HBsAg and greater than 2.15 mM for HBeAg. It is beneficial for research focusing on HBV infection and therapeutic development against hepatitis B.

HBV/HDV-IN-5 is a potent inhibitor targeting hepatitis B virus (HBV) and hepatitis D virus (HDV). This compound exhibits significant antiviral activity, making it valuable for research focused on viral hepatitis. HBV/HDV-IN-5 is primarily utilized in studies exploring antiviral therapies and the mechanisms underlying HBV and HDV infections.

Periglaucine A is a hasubanane-type alkaloid that targets anti-HBV and anti-HIV-1 activity. It effectively inhibits the secretion of HBV surface antigen (HBsAg) in Hep G2.2.15 cells, demonstrating its potential as a therapeutic agent against hepatitis B virus. Additionally, Periglaucine A exhibits anti-HIV-1 efficacy in C8166 cells, with an EC50 value of 204 μM, making it a valuable compound for research in viral infections.

Acutumidine is an alkaloid known for its anti-HBV activity, derived from the plant Hypserpa nitida Miers. This compound effectively inhibits the production of hepatitis B surface antigen (HBsAg) in Hep G2.2.15 cells that are stably transfected with the HBV genome, demonstrating an IC50 value of 2.023 mM. Acutumidine shows potential for research applications in the study of hepatitis B virus infection and its pathways.

Morphothiadin mesylate is a potent inhibitor of Hepatitis B Virus (HBV) replication, targeting both wild-type and Adefovir-resistant strains. With an IC50 value of 12 nM, it demonstrates significant antiviral activity. This compound is useful for research applications focused on HBV pathogenesis and the development of antiviral therapeutic strategies.

HBV-IN-49 is an anti-hepatitis B virus (HBV) agent that specifically inhibits HBV replication. It is valuable for studying HBV infection dynamics and evaluating therapeutic strategies against hepatitis B virus-related diseases. This compound serves as an essential tool for researchers investigating antiviral mechanisms and potential treatments.

Coclauril is a potent inhibitor of Hepatitis B virus (HBV) replication, acting primarily on hepatocytes. It demonstrates antiviral activity in human hepatoblastoma cell lines, with an EC50 value of 7.6 μg/mL. Coclauril is utilized in research to explore therapeutic strategies against HBV and to study the mechanisms of viral replication inhibition.

BAY39-5493 is a non-nucleoside inhibitor targeting hepatitis B virus (HBV) replication. It exerts its biological activity by blocking the formation of viral core particles, thereby inhibiting viral DNA replication. With an IC50 value of 0.03 μM against HBV in stably transfected HepG2.2.15 cells, BAY39-5493 serves as a valuable tool for research in the field of antiviral therapeutics and HBV biology.

BAY38-7690 is a non-nucleoside inhibitor that specifically targets hepatitis B virus (HBV) replication. It functions by obstructing the assembly of viral core particles, thereby inhibiting viral DNA replication. With an IC50 value of 0.15 μM in stably transfected HepG2.2.15 cells, BAY38-7690 is an important tool for investigating HBV biology and evaluating potential therapeutic strategies against hepatitis B virus infections.

KR-26556 is a sulfonamide compound that acts as a hepatitis B virus (HBV) capsid assembly regulator. It demonstrates potent anti-HBV activity with an EC50 value of 0.04 μM and exhibits favorable safety profiles. This reagent is suitable for investigating chronic hepatitis B and its associated therapeutic mechanisms.

Personalised postprandial-targeting is an HBV inhibitor that modulates water-heme interactions, specifically targeting low-spin cytochrome P450 complexes. This reagent effectively preserves the axial water ligands of CYP2C9, even when inhibitors are present, enabling advanced studies of enzyme dynamics. Additionally, it facilitates the observation of hydrogen atoms in the axial water ligands through EPR spectroscopy, offering valuable insights into the active site of the enzyme, making it a critical tool for research in enzymology and drug development.

GS-8873 TFA is a potent inhibitor of hepatitis B virus (HBV) surface antigen (HBsAg) production, exhibiting an EC50 value of 4 nM. This orally bioavailable compound demonstrates favorable pharmacokinetic properties in rodent models and metabolic stability in human hepatocytes. Notably, GS-8873 TFA has been associated with neurofunctional deficits in both rats and cynomolgus monkeys, making it a valuable tool for research in HBV therapies and associated neurological effects.

FMAU is a nucleoside analog that primarily inhibits the replication of hepatitis B virus (HBV) and Epstein-Barr virus (EBV). Once phosphorylated by human thymidine kinase, FMAU is incorporated into DNA, serving as a valuable marker for cell proliferation. Its research applications extend to studies on herpes simplex virus infection and various cancer types.

Telbivudine is an orally active thymidine nucleoside analog that acts as an inhibitor of hepatitis B virus (HBV) replication. Its potent antiviral activity makes it valuable in the study of HBV-related pathologies and the development of antiviral therapies. This compound serves as a significant tool for researchers investigating HBV dynamics and therapeutic interventions.

Catalpol, an iridoid glycoside derived from Rehmannia glutinosa, primarily targets hepatitis B virus (HBV) inhibition. It exhibits a broad range of biological activities including neuroprotection, hypoglycemic effects, anti-inflammatory properties, and antioxidant effects. Additionally, Catalpol demonstrates potential in anti-cancer and anti-spasmodic applications, making it valuable for various research contexts focusing on viral infections and related therapeutic interventions.